Intensity Therapeutics Raises $4 Million to Advance Intratumoral Cancer Therapy Clinical Trials
核心洞察
Intensity Therapeutics completed a $4 million registered direct offering to fund advancement of clinical trials for its novel intratumoral cancer therapies.
The company's proprietary non-covalent conjugation technology is designed to kill tumors and enhance immune system recognition of cancers.
The funding extends the company's cash runway until the end of the first quarter of 2027, supporting continued development of its late-stage clinical programs.
Intensity Therapeutics, Inc. (Nasdaq: INTS) announced the pricing of a $4 million registered direct offering to advance its clinical trials for novel intratumoral cancer therapies. The late-stage clinical biotechnology company entered into a securities purchase agreement with a new long-term fundamental investor for 5,000,000 shares of common stock at $0.80 per share.
The offering is expected to close on or about November 3, 2025, subject to customary closing conditions. A.G.P./Alliance Global Partners (搜索) is serving as the sole placement agent for the transaction.
Proprietary Technology Platform
Intensity focuses on the discovery and development of intratumoral cancer therapies using its proprietary non-covalent conjugation technology. The company's approach is designed to kill tumors and increase immune system recognition of cancers, representing a novel therapeutic strategy in oncology.
Financial Impact and Strategic Use of Proceeds
The company expects to use the net proceeds from the offering for the advancement of clinical trials, working capital, and general corporate purposes. Upon closing, Intensity anticipates having sufficient cash runway until the end of the first quarter of 2027, providing substantial financial runway for continued clinical development.
Regulatory Framework
The offering is being conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 333-280681), which was declared effective by the Securities and Exchange Commission on July 11, 2024. A prospectus supplement and accompanying base prospectus relating to the registered direct offering will be filed with the SEC and made available through standard regulatory channels.
The transaction represents a strategic funding milestone for Intensity as it continues to advance its late-stage clinical programs in the competitive oncology therapeutics landscape.